Industry M&A Weekly: Moneris' $1.44B Sale, Jazz's $1.32B Actio Deal, and Two More

Four disclosed transactions met the channel's inclusion bar between August 5 and August 12, 2026 (UTC). The largest was Francisco Partners' C$2.0 billion cash purchase of Moneris, a Canadian payments platform jointly owned by RBC and BMO. In biotech, Jazz bought Actio Biosciences for $820 million up front plus up to $500 million in milestones, while Tarsus agreed to buy Alkeus for $450 million up front plus up to $350 million in milestones. Teledyne added Varex Imaging for about $1.1 billion in cash, extending a sensing portfolio into medical and industrial X-ray components.

The common thread is control of a specialized operating layer: payment acceptance, rare-disease development, or the components that sit inside diagnostic and inspection systems. The contracts differ, so the headline values are not interchangeable.

Francisco Partners agreed to acquire Moneris from Royal Bank of Canada and Bank of Montreal for approximately C$2.0 billion in cash. The U.S. dollar value was about $1.44 billion at the exchange rate cited by Reuters. RBC and BMO will each receive half of the proceeds. 1

Moneris has powered Canadian commerce for more than 25 years. It helps businesses accept and manage payments at more than 325,000 points of commerce, which the company says represent one in three transactions in Canada. Its product set covers ecommerce and omnichannel payments, point-of-sale hardware and software, integrated business tools, and data and insights. 2

The structure preserves part of the banks' commercial connection to the platform. RBC and BMO will enter long-term referral agreements with Moneris and keep ongoing commercial relationships after the sale. The transaction remains subject to regulatory approvals, including requirements under Canada's Retail Payment Activities Act and Competition Act, and is expected to close by the end of the first quarter of the banks' fiscal 2027. 2

For Francisco Partners, the purchase is a payments-platform investment rather than a greenfield build. The firm cited its experience with payments and fintech businesses and said it plans to fund platform expansion, innovation, and growth. Moneris also named Jeff Sloan, the former president and CEO of Global Payments, as chairman. 2

The important distinction is who controls the asset after closing. The banks give up ownership, but the referral agreements keep them connected to the customer flow. Francisco Partners gets the operating platform and the freedom to invest behind it without having to rebuild Moneris' Canadian distribution from scratch.

Jazz agreed to acquire privately held Actio Biosciences for $820 million up front and up to $500 million in contingent consideration tied to regulatory approval and sales milestones. The companies expect the deal to close in the fourth quarter of 2026, subject to customary conditions. Jazz plans to fund it with cash on hand and existing financing facilities. 3

Actio's lead asset is ABS-1230, an oral small-molecule inhibitor of the KCNT1 ion channel. KCNT1-related epilepsy is a rare genetic developmental and epileptic encephalopathy affecting approximately 2,500 people in the United States, with no FDA-approved therapy. An early proof-of-concept trial in children showed meaningful seizure reductions, and the ongoing Phase 1b/2a KYRON trial is intended to support a future U.S. application. 3

Actio was founded around the idea that genetic and disease-biology insights can produce precision medicines for rare conditions and later inform treatment of more common disorders. The company was advancing two clinical-stage programs: ABS-1230 for KCNT1-related epilepsy and ABS-0871, a TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C, alongside an earlier genetic-epilepsy program. 3

Jazz's rationale is unusually specific. ABS-1230 extends the company's rare-epilepsy position around Epidiolex, while Jazz supplies the development and commercial infrastructure that Actio does not have at the same scale. The deal also separates one asset from the rest of Actio: certain management, employees, and programs will move into a new private company, in which Jazz will hold a minority stake. 3

That makes the $1.32 billion maximum value a milestone-dependent pipeline price, not a cash check at signing. The clinical readout and regulatory path still determine how much of the contingent consideration becomes payable.

Teledyne Technologies agreed to buy Varex Imaging for $18.90 per share in cash, valuing the transaction at approximately $1.1 billion. The companies expect the deal to close in early 2027. Teledyne said the acquisition will broaden its healthcare portfolio, which already includes imaging and sensing technologies for medical, dental, and life-science applications. 4

Varex supplies X-ray imaging components to original-equipment manufacturers. Its portfolio includes X-ray tubes, flat-panel and photon-counting detectors, high-voltage connectors, imaging software, and related products for medical, security, and industrial inspection. Its 2025 filing says the company had approximately 2,400 full-time-equivalent employees and produced more than 27,000 X-ray tubes and 20,000 detectors annually. 6

The installed base matters here. Varex's filing describes more than 160,000 X-ray tubes and 170,000 detectors in the field, plus hundreds of thousands of connection and control components. Replacement and service revenue tied to that installed base is a significant part of the business. 6

Teledyne is therefore buying more than a catalog of components. It is buying design-ins with equipment makers, manufacturing scale, and a recurring replacement cycle that touches medical diagnosis, airport and cargo inspection, and industrial quality control. Varex CEO Sunny Sanyal said Teledyne's resources could accelerate adoption of Varex's imaging products and development of the next generation. 4

The transaction sits between biotech and infrastructure in the channel's classification. It is healthcare technology, but its economics are driven by components, OEM relationships, and replacement demand rather than a drug's clinical milestones.

Tarsus agreed to acquire Alkeus Pharmaceuticals for approximately $450 million up front: $270 million in cash and $180 million in Tarsus stock. Alkeus shareholders can receive up to $350 million in regulatory and first-sale milestones, plus low-single-digit tiered royalties on gildeuretinol net sales. The deal is expected to close in 2026, subject to customary conditions. 5

Alkeus' lead program is gildeuretinol, also known as ALK-001, a once-daily oral investigational medicine for Stargardt disease. The small molecule is designed to reduce the formation of toxic vitamin A dimers while preserving the normal visual cycle. Stargardt is an inherited retinal disease that progressively damages central vision and has no FDA-approved therapy. 5

The target brings a late-stage program rather than an early discovery platform. More than 400 people have received ALK-001, some for more than seven years. Tarsus cited data showing a 29.5% slower annualized growth rate of retinal atrophic lesions in one study and an 87% lower likelihood of significant low-light visual-acuity loss in another. The Phase 3 NORTHSTAR study is expected to enroll approximately 230 patients, with top-line data expected in the second half of 2029. 5

Tarsus said the acquisition expands its presence in retina and complements the capabilities it gained through the acquisition of iRenix Medical. The buyer is taking on a defined Phase 3 risk with a long wait to the readout; the cash-and-stock structure and contingent payments keep part of that risk outside the up-front price. 5

Moneris is embedded in merchant checkout and commerce operations. Varex components are designed into imaging systems and supported through an installed base. Jazz and Tarsus are buying clinical programs that already have a defined disease, development path, and specialist knowledge behind them. In each case, the buyer starts with a working position in a customer, manufacturing, or clinical workflow rather than an empty product roadmap. 2356

Jazz's $820 million up front is paired with up to $500 million in milestones. Tarsus' $450 million up front is paired with up to $350 million in milestones and future royalties. Both buyers are paying enough to secure control now while leaving part of the final price dependent on approval, launch, or sales. That is not the same risk profile as Moneris' C$2.0 billion cash consideration or Teledyne's $1.1 billion all-cash offer. 35

Francisco Partners gets Moneris' Canadian payments footprint and keeps RBC and BMO connected through referral agreements. Teledyne gets Varex's OEM relationships and installed-base service cycle. Jazz and Tarsus each add a specialized program to an existing commercial or clinical focus. The buyer's advantage is therefore partly the target's technology and partly the route already built around it. 234

This issue covers transaction disclosures from August 5 through the August 12 publication cutoff in UTC. Four deals met the minimum count and had accessible evidence for value, structure, status, buyer rationale, and target or platform background. The Jazz and Tarsus totals include contingent consideration; only their up-front components are payable at signing or closing under the disclosed terms. Moneris' C$2.0 billion is the official transaction currency; the approximately $1.44 billion figure is Reuters' conversion. A number of additional technology announcements were left out when the available source did not disclose transaction economics, because the channel's deal entries require a value or an explicit estimate.